BLUE vs. ALVR, SGMO, JSPR, AURA, TRML, STRO, CCCC, AVXL, TNYA, and AGEN
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include AlloVir (ALVR), Sangamo Therapeutics (SGMO), Jasper Therapeutics (JSPR), Aura Biosciences (AURA), Tourmaline Bio (TRML), Sutro Biopharma (STRO), C4 Therapeutics (CCCC), Anavex Life Sciences (AVXL), Tenaya Therapeutics (TNYA), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
AlloVir (NASDAQ:ALVR) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
AlloVir has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
In the previous week, bluebird bio had 1 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for bluebird bio and 1 mentions for AlloVir. bluebird bio's average media sentiment score of 1.91 beat AlloVir's score of 0.51 indicating that AlloVir is being referred to more favorably in the media.
AlloVir has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
bluebird bio received 1008 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
AlloVir currently has a consensus target price of $18.50, indicating a potential upside of 2,358.47%. bluebird bio has a consensus target price of $5.46, indicating a potential upside of 503.59%. Given bluebird bio's higher probable upside, equities research analysts plainly believe AlloVir is more favorable than bluebird bio.
66.1% of AlloVir shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 33.9% of AlloVir shares are owned by insiders. Comparatively, 2.1% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
AlloVir has a net margin of 0.00% compared to AlloVir's net margin of -419.64%. AlloVir's return on equity of -34.32% beat bluebird bio's return on equity.
Summary
bluebird bio beats AlloVir on 11 of the 17 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bluebird bio Competitors List
Related Companies and Tools
